This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The intervention was a post-splenectomy registry approach for the delivery of treatment interventions. The comparator was the hypothetical counter-factual of no post-splenectomy register. In each cohort, patients were offered three treatments: vaccination, education and antibiotics. Vaccination was assumed to comprise of an initial receipt of routine vaccinations (pneumococcal, Haemophilus influenzae type B, influenza and meningococcal), followed by annual influenza vaccination and five-yearly booster vaccinations for pneumococcus and meningococcus. Chemoprophylaxis constituted universal antibiotics for two years post-splenectomy, and additional penicillin and amoxicillin for 50% of people. Education consisted of one initial education session with a registry nurse and an annual newsletter.
Location/setting
Australia/out-patient.
Methods

Analytical approach:
A Markov decision model was developed to estimate the lifetime costs and benefits of a post-splenectomy register. Outcomes for a cohort of 1,000 people covered by a registry were compared to 1,000 people not on a registry. The average age on entry was 48 years. Inputs for the model were derived from real-world hospital data (Alfred Hospital) and existing observational studies. The cost-effectiveness of the registry compared to no registry was estimated in terms of the additional cost per case of overwhelming post-splenectomy infection (OPSI) and as the additional cost per lifeyear gained. The authors stated that the analysis was conducted from the perspective of the health care sector.
Effectiveness data:
The primary effectiveness input was the relative uptake rates of the three treatment interventions (vaccination, education and antibiotics) for the two cohorts. For the non-registry cohort, uptake rates were derived from one published study from the literature (90% for vaccination, 67% for Chemoprophylaxis and 22% for education). Uptake rates for the registry cohort were assumed to be 100%. OPSI risk reduction was estimated for patients who received the following treatment combinations: all three treatments; vaccination and chemoprophylaxis; vaccination only. These reduction rates and the baseline OPSI rate were derived from the literature (two published papers). Mortality following OPSI was estimated from the literature to be 50%. The authors assumed (stating a lack of data to the contrary) that the cohort population had an equivalent life expectancy to the general population of Victoria, and that OPSI survivors did Several strong assumptions were adopted regarding the effectiveness of the intervention and the subsequent treatments. In particular the authors did not justify their assumption that the registry would result in 100% uptake of treatment. This assumption seems particularly strong for chemoprophylaxis and education, which both had uptake rates significantly lower than 100% in the non-registry cohort. The authors highlighted that a limitation of their study was the lack of available data, and stated that there were no randomised controlled trials of the effectiveness of a registry, or of the interventions. The reliance on non-randomised comparative data means that the results were more likely to be susceptible to bias.
Costs:
The costs included were appropriate to the perspective. The costs were appropriate to the population and setting, having been derived directly from data from the hospital in which the registry was conducted. Future costs were appropriately discounted. The unit costs applied in the model were clearly reported.
Analysis and results:
Only limited details of the model were reported. In particular the model structure was not reported, so the appropriateness of the model structure could not be assessed. The results of the analysis were clearly reported. No justification for the choice of parameter ranges used in the sensitivity analysis was given. It was unclear whether these ranges accurately reflected expected parameter uncertainty. Only a limited univariate deterministic sensitivity analysis was conducted, which was unlikely to adequately assess the effect of parameter uncertainty on the results. A probabilistic analysis (in which parameter values are drawn simultaneously from assigned probability distributions in order to assess the effect of joint uncertainty on the results) would have provided a more accurate assessment but the data may not have been available to undertake such an analysis. The interpretation of the results should account for the ranges selected for the sensitivity analyses. Given that the effectiveness and cost inputs were taken from a specific Australian hospital setting, the reader should carefully consider the applicability of the study (in particular the parameter estimates) to their situation before generalising the results.
Concluding remarks:
There are some limitations in the study methodology which mean the authors conclusions should be used with caution. In particular the analysis suffered from a lack of data and strong assumptions regarding efficacy.
